Faeezah Patel

Datos Biográficos

ID8932012
NOMBREFaeezah Patel
NOMBRESFaeezah
APELLIDOPatel
FIRMAPATEL F
AFILIACIONESUniversity of the Witwatersrand
ORCID0000-0003-1503-2016
VERIFICADOSí
TOTAL DE OBRAS7
TOTAL DE CITAS0
TOTAL COMO AUTOR7
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2017
AÑO MÁS RECIENTE DE PUBLICACIÓN2025
ÍNDICE H0

  • Oral health and behavioral problems in children living with and without HIV in South Africa

    Open AccessAna Barrios-Tascon, Ana Barrios et al.ARTICLEAIDS Care2025

    The prevalence of behavioral problems in children and adolescents living with HIV is high. We investigate associations between oral microbiota and behavioral problems in children living with HIV (CLWH) and children who are HIV-uninfected (CHU). Oral swab samples, assessment of behavioral functioning using the Strengths and Difficulties Questionnaire (SDQ), and clinical and social data were collected from 477 CLWH and 123 CHU at two sites in Johan…

  • Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

    Open AccessCatherine Riou, Jinal N Bhiman et al.ARTICLEPLOS Global Public Health2024

    We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 …

  • Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa

    Open AccessNigel Garrett, Tarylee Reddy et al.ARTICLEPLOS Global Public Health2024

    Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…

  • Disclosure to South African children about their own HIV status over time

    Melody Wu, Stephanie Shiau et al.ARTICLEAIDS Care2023

    Disclosure to children living with HIV (CLHIV) about their own status is associated with positive outcomes such as treatment adherence, but prior cross-sectional studies in sub-Saharan Africa report disclosure rates of <50%. This study aims to assess pediatric disclosure over time. 548 CLHIV were followed from 2/2013-4/2018 in Johannesburg, South Africa. Cumulative incidence of disclosure was calculated with Kaplan-Meier analysis, and disclosure …

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against Sars-CoV-2

    Open AccessMerryn Voysey, Sue Ann Costa Clemens et al.ARTICLEThe Lancet2021

    Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Afri…

  • Educational delays among children living with perinatally-acquired HIV in Johannesburg, South Africa

    Stephanie Shiau, Stephen M Arpadi et al.ARTICLEAIDS Care2020

    Little is known about how growing up with HIV impacts educational outcomes in sub-Saharan African children. We evaluated if South African children living with HIV (CLWH) were in the appropriate school grade-for-age compared to uninfected control children. We observed higher rates of not being in the correct grade-for-age in CLWH compared with controls (OR 3.32, 95% CI: 2.07-5.34), adjusted for study site, sex, whether the child's biological fathe…

  • Extent of disclosure

    Pamela M Murnane, Stacy-Lee Sigamoney et al.ARTICLEAIDS Care2017

    How and when to disclose a positive HIV diagnosis to an infected child is a complex challenge for caregivers and healthcare workers. With the introduction of antiretroviral therapy, pediatric HIV infection has transitioned from a fatal disease to a lifelong chronic illness, thus increasing the need to address the disclosure process. As HIV-infected children mature, begin to take part in management of their own health care, and potentially initiat…